Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting
Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;
Two Antigens Prevent Disease Driven by Many Autoantigens Demonstrating Bystander Suppression
Findings Potentially Translatable to Multiple T Cell-Mediated Autoimmune Diseases
“We believe these new preclinical data, part of an ongoing experiment, demonstrate prevention of diabetes and bystander suppression in the non-obese diabetes, or NOD, preclinical model, the primary model used for studying autoimmune diabetes that has striking similarities to the human disease,” said
Induction of Antigen-Specific Immune Tolerance in Type 1 Diabetes by Antigen-Expressing Re Cell Therapeutics
Abstract Number: TPS2690
- Demonstrated tolerance induction and bystander suppression in stringent type 1 diabetes preclinical models
- From ongoing experiment, showed efficacy in the NOD preclinical model
- By increasing to 3 doses administered and optimizing the dosing schedule, results at 25 weeks exhibit bystander suppression by delivering only two antigens, indicating disease prevention caused by many autoantigens (0/5 mice)
- Previously reported data at 25 weeks with two doses prevented or delayed disease onset (7/15 mice)
- Established efficacy in the BDC2.5 adoptive transfer model with data supporting that repeated dosing extends duration of disease protection, reverses established inflammation, which is important for the treatment of existing autoimmunity, and induces two types of regulatory T cells, resulting in protection against re-challenge
- These findings are potentially translatable beyond type 1 diabetes to multiple autoimmune diseases, including multiple sclerosis and celiac disease.
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding beliefs about the efficacy of its Red Cell Therapeutics and beliefs and analyses of the data from Rubius’ type 1 diabetes program, including that it is potentially translatable into multiple T-cell mediated autoimmune diseases . The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the development of our Red Cell Therapeutic product candidates and their therapeutic potential, our ability to execute on our plans and expectations, our analyses of clinical and preclinical data, including the type 1 diabetes program, and other risks identified in our filings with the
Contacts
Investors
lori.murray@rubiustx.com
Media
marissa.hanify@rubiustx.com

Source: Rubius Therapeutics